Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06893380Recruiting
Drug combo plus immunotherapy for advanced bile duct cancer
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07050940Recruiting
Adding a gut supplement to immunotherapy for advanced melanoma
This trial tests whether adding a postbiotic (a gut-health supplement) to a standard immunotherapy called anti-PD-1 makes it work better for people with advanced melanoma that hasn't been treated yet. It may help shrink tumors or slow the cancer's growth.
Bari, BAAges 18 years+ - NCT07066917Recruiting
Breast cancer treatment response study
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
AthensAges 18 years+ - NCT07071337RecruitingPhase 3
Study of SKB264 vs chemo for HR+/HER2- breast cancer after hormone therapy
This trial tests a new drug, SKB264, against standard chemotherapy for people with a common type of breast cancer (HR+/HER2-) that has spread and stopped responding to hormone therapy. It may offer a new option if you haven't had chemotherapy for advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07081984RecruitingPhase 1
Testing TI-0093 for advanced HPV-16 positive cancers
This study tests a new drug, TI-0093, for people with HPV‑16 positive solid tumors (like head and neck or cervical cancer) that have come back or spread after standard treatments. The goal is to see if the drug can help shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT07084558Recruiting
Testing treatment guided by tumor DNA for hormone positive breast cancer
This trial tests whether using a blood test (circulating tumor DNA) can help guide chemo and hormone therapy for early-stage, hormone receptor positive and HER2 negative breast cancer. The goal is to tailor treatment to your tumor's response, potentially reducing unnecessary side effects.
Vienna, AustriaAges 18–100 - NCT07132190RecruitingPhase 2
Radiation for growing brain tumors with same-day planning
This study tests whether a precise, one-day radiation treatment for brain tumors that are growing or in tricky spots can be effective with a smaller safety margin. It's designed for people whose brain tumors are changing quickly or sitting near areas of swelling or recent surgery.
Boston, MassachusettsAges 18 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07195513Recruiting
Helping advanced cancer patients connect to palliative care via electronic reporting
This trial uses electronic surveys to identify symptoms and unmet needs in people with advanced cancer, then connects them to palliative care services. It aims to improve quality of life by making sure patients get the extra support they need.
Lebanon, New HampshireAges 18 years+ - NCT07241793RecruitingPhase 2
Trastuzumab rezetecan with or without immunotherapy for advanced bladder cancer
This trial tests a new drug combination for people with advanced bladder cancer that has a protein called HER2 on its surface. It may help those whose cancer has spread or cannot be removed with surgery. The study looks at the drug given alone or with an immunotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT02926690RecruitingPhase 1
MELK inhibitor safety study for advanced breast cancer
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Norwalk, ConnecticutAges 18 years+ - NCT06098560Recruiting
ctDNA as a marker for immunotherapy in advanced colorectal cancer
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Beijing, Beijing MunicipalityAges 18–80 - NCT02600949Enrolling by invitationPhase 1
Peptide vaccine study for advanced pancreatic or colon cancer
This Phase 1 study tests a personalized vaccine made from a patient’s tumor to help the immune system recognize and attack cancer. It is for people with advanced pancreatic or colorectal cancer (often after surgery or while metastatic) and aims to see if the approach is safe and can help immune control of the cancer.
Houston, TexasAges 18 years+ - NCT07480928RecruitingPhase 1/Phase 2
CAR-NK cell therapy for advanced pancreatic cancer
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT07486089RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for advanced breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments and need new options.
Shenzhen, GuangdongAges 18–75 - NCT07492628RecruitingPhase 1
Dual-target cell therapy for advanced bladder cancer
This trial tests a new treatment that uses your own immune cells, called CAR-NK cells, modified to attack two proteins (Nectin-4 and HER2) often found on bladder cancer cells. It is for people whose cancer has spread or cannot be removed by surgery and has not responded to standard treatments like chemotherapy or immunotherapy.
Shenzhen, GuangdongAges 18–75 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT07582887Recruiting
Genetic Testing to Predict Side Effects from Breast Cancer Antibody Drugs
This study examines how genetic differences affect how your body handles three newer breast cancer medications (Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan). A blood test will check your UGT1A1 gene to help doctors predict which side effects you might experience and adjust your treatment accordingly.
Granada, GranadaAges 18 years+
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,366 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.